BioSpace News Archive

RELIEF THERAPEUTICS Holding SA reported that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc., has announced it has agreed with Hungarian Health Officials on a regulatory path for emergency use of aviptadil in the Central European region, beginning with a compassionate care program, expected to begin by the end of 2021.

Active Biotech announced that the first subject has been dosed in the phase I clinical study of the newly developed eye-drop formulation of the company’s candidate drug laquinimod.

Genentech, a member of the Roche Group, announced new follow-up efficacy, safety and patient-reported outcomes data from the Phase II CITYSCAPE trial, investigating the novel anti-TIGIT cancer immunotherapy tiragolumab plus Tecentriq® compared with Tecentriq alone as an initial treatment for people with PD-L1-positive metastatic non-small cell lung cancer.

Leica Microsystems, a technology leader in microscope and image analysis solutions, announces an increased market representation for its neurosurgical, spine, ophthalmic, otolaryngologic, dental and plastic reconstructive microscope sales.

SpringWorks Therapeutics, Inc. today announced that the company has entered into a clinical trial collaboration agreement with AbbVie, Inc. to evaluate nirogacestat, SpringWorks’ investigational gamma secretase inhibitor.

Nevro Corp. today announced that D. Keith Grossman , Nevro’s Chairman, CEO and President will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 7:30 am Pacific Time / 10:30 am Eastern Time at the Westin St. Francis Hotel in San Francisco, CA.

BioInvent International AB today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), China’s medical product regulator, has approved a Clinical Trial Application (CTA) submitted by BioInvent’s licensee in China, CASI Pharmaceuticals (CASI).

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced that on December 6, 2021, the compensation committee of BridgeBio’s board of directors granted nine new employees restricted stock units for an aggregate of 12,073 shares of the Company’s common stock.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 32nd International Symposium on ALS/MND including an analysis of baseline characteristics from the initial patients enrolled in COURAGE-ALS.

TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of data presentations at the upcoming 63 rd American Society of Hematology (ASH) annual meeting and exposition, to be held December 11 – 14, 2021, virtually and also live at the Georgia World Congress Center in Atlanta, Georgia.